Compare Ascendis Pharma A/S (ASND) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Oxford Lane Capital Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Oxford Lane Capital Corp trades at $9.18 (market cap $891.54M). The key difference: Ascendis Pharma A/S is far larger — about 19.9× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OXLC | |
|---|---|---|
Market Cap | $17.74B | $891.54M |
Sector | Health | Financials |
52-Week High | $277.18 | $20.80 |
52-Week Low | $163.32 | $8.15 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
OXLC trades at $9.13, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI readings. The company reported a net income margin exceeding 100% for 2025, yet recent quarterly earnings have consistently missed expectations, including a significant loss in Q1 2026. Dividend payments remain active, but negative ROE and ROA highlight financial strain. Analyst sentiment is divided, with a 50% buy rating amid concerns over net asset value declines and high distribution yields.
The outlook for OXLC is clouded by severe profitability challenges and volatile earnings, presenting high risk. While the dividend yield attracts income seekers, sustained NAV erosion and operational cash outflows signal underlying weakness. Investment opportunity hinges on a turnaround in CLO equity markets, but current fundamentals suggest caution is warranted for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
